Skip to main content
. 2022 Nov 24;14(12):826. doi: 10.3390/toxins14120826

Figure 1.

Figure 1

Human Biomonitoring and Risk Assessment of mycotoxins (compliance with RA components). AOP—adverse outcome pathway, HBM-GV—Human Biomonitoring Guidance Value.